Baseline Characteristics in Part 1 of the ongoing ANDECAL Study, a two-part Phase 2/3 Study of andecaliximab (anti-matrix metalloproteinase-9 mAb) in participants with Fibrodysplasia Ossificans Progressiva (FOP)

andecaliximab (GS-5745) - āshibio

Mona Al Mukaddam; Edward C. Hsiao , MD, PhD; Frederick S. Kaplan , MD; Robert Pignolo , MD, PhD; Deborah Wenkert , MD; Kelly Wentworth , MD

Jul 31, 2026